Drug Profile

ONKT 102

Alternative Names: ONKT-102

Latest Information Update: 29 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ONK Therapeutics; VU University Medical Center
Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Multiple myeloma

Most Recent Events

29 Apr 2025 ONKT 102 is still in preclinical phase for Multiple myeloma in Ireland (ONK Therapeutics pipeline; April 2025)
29 Aug 2022 Pharmacodynamics data from preclinical studies in Multiple myeloma released by ONK Therapeutics
09 Sep 2021 ONK Therapeutics has patent protection for CISH knockout in NK cells for use in cancer therapies in the US

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com